Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli.
暂无分享,去创建一个
S. Sushanth Kumar | S. Guru | N. Kalia | Shashikanta Sau | Sandeep Sharma | Arnab Roy | Puja Kumari Agnivesh
[1] Vishvanath Tiwari,et al. Anti-persister strategies against stress induced bacterial persistence. , 2022, Microbial pathogenesis.
[2] R. Chikhale,et al. Challenges in Targeting Mycobacterial ATP Synthase: The Known and Beyond , 2022 .
[3] Samreen Fatima,et al. Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals , 2021, MedComm.
[4] K. Rhee,et al. Growth of Mycobacterium tuberculosis at acidic pH depends on lipid assimilation and is accompanied by reduced GAPDH activity , 2021, Proceedings of the National Academy of Sciences.
[5] V. Nandicoori,et al. Redox homeostasis in Mycobacterium tuberculosis is modulated by a novel actinomycete‐specific transcription factor , 2021, The EMBO journal.
[6] W. Denny. Inhibitors of F1F0ATP synthase enzymes for the treatment of tuberculosis and cancer. , 2021, Future medicinal chemistry.
[7] X. Guan,et al. Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy , 2021, Metabolites.
[8] J. Rubinstein,et al. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline , 2020, Nature.
[9] C. Nathan,et al. Biology of antimicrobial resistance and approaches to combat it , 2020, Science Translational Medicine.
[10] L. Tsenova,et al. Effects of host‐directed therapies on the pathology of tuberculosis , 2020, The Journal of pathology.
[11] N. Chandel,et al. Mitochondrial TCA cycle metabolites control physiology and disease , 2020, Nature Communications.
[12] P. Nahid,et al. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials , 2019, PLoS medicine.
[13] R. Nair,et al. Mycobacterium smegmatis moxifloxacin persister cells produce high levels of hydroxyl radical, generating genetic resisters selectable not only with moxifloxacin, but also with ethambutol and isoniazid. , 2019, Microbiology.
[14] Charles L. Dulberger,et al. The mycobacterial cell envelope — a moving target , 2019, Nature Reviews Microbiology.
[15] R. B. Abramovitch,et al. Acid Fasting: Modulation of Mycobacterium tuberculosis Metabolism at Acidic pH. , 2019, Trends in microbiology.
[16] Kishor Jakkala,et al. Hypoxic Non-replicating Persistent Mycobacterium tuberculosis Develops Thickened Outer Layer That Helps in Restricting Rifampicin Entry , 2019, Front. Microbiol..
[17] C. Vilchèze,et al. The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis. , 2019, Journal of molecular biology.
[18] Sang-Nae Cho,et al. Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis , 2019, Nature Communications.
[19] Naveed Sabir,et al. Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy , 2019, Cells.
[20] T. Parish,et al. The relevance of persisters in tuberculosis drug discovery. , 2019, Microbiology.
[21] J. Collins,et al. Publisher Correction: Definitions and guidelines for research on antibiotic persistence , 2019, Nature Reviews Microbiology.
[22] Alimuddin Zumla,et al. The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world? , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[23] Arun Sharma,et al. Mycobacterium tuberculosis Rv0366c-Rv0367c encodes a non-canonical PezAT-like toxin-antitoxin pair , 2019, Scientific Reports.
[24] S. Hasnain,et al. Mycobacterium Tuberculosis: Molecular Infection Biology, Pathogenesis, Diagnostics and New Interventions , 2019 .
[25] Prabhakar Tiwari,et al. Structural, functional and biological insights into the role of Mycobacterium tuberculosis VapBC11 toxin–antitoxin system: targeting a tRNase to tackle mycobacterial adaptation , 2018, Nucleic acids research.
[26] T. Tuller,et al. Genome-wide analysis of horizontally acquired genes in the genus Mycobacterium , 2018, Scientific Reports.
[27] R. Slayden,et al. Toxin-antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis. , 2018, Pathogens and disease.
[28] M. Fauvart,et al. Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[29] Bryan D. Bryson,et al. Posttranslational modification of a histone-like protein regulates phenotypic resistance to isoniazid in mycobacteria , 2018, Science Advances.
[30] D. Schnappinger,et al. Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis , 2018, Nature Reviews Microbiology.
[31] Naveed Sabir,et al. miRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy , 2018, Front. Microbiol..
[32] J. Collins,et al. Targeting Antibiotic Tolerance, Pathogen by Pathogen , 2018, Cell.
[33] D. Hung,et al. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets. , 2018, ACS infectious diseases.
[34] Shweta Sharma,et al. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality? , 2017, Infectious diseases.
[35] Sumit Sharma,et al. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis. , 2018, Tuberculosis.
[36] N. Dillon,et al. Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA , 2017, Scientific Reports.
[37] Madavan Vasudevan,et al. Co-expression network analysis of toxin-antitoxin loci in Mycobacterium tuberculosis reveals key modulators of cellular stress , 2017, Scientific Reports.
[38] J. Sperry,et al. Targeting isocitrate lyase for the treatment of latent tuberculosis. , 2017, Drug discovery today.
[39] M. Berney,et al. Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection , 2017, Proceedings of the National Academy of Sciences.
[40] E. Rubin,et al. Deletion of a mycobacterial divisome factor collapses single-cell phenotypic heterogeneity , 2017, Nature.
[41] D. Moody,et al. Metabolic anticipation in Mycobacterium tuberculosis , 2017, Nature Microbiology.
[42] R. Fisher,et al. Persistent bacterial infections and persister cells , 2017, Nature Reviews Microbiology.
[43] B. Görke,et al. Roles of Regulatory RNAs for Antibiotic Resistance in Bacteria and Their Potential Value as Novel Drug Targets , 2017, Front. Microbiol..
[44] D. Ramos,et al. Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis , 2017, Front. Microbiol..
[45] Joel S. Freundlich,et al. Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis , 2017, Proceedings of the National Academy of Sciences.
[46] T. Parish,et al. Antituberculosis drugs: reducing efflux=increasing activity. , 2017, Drug discovery today.
[47] P. Kirchhoff,et al. Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence. , 2017, Nature chemical biology.
[48] Yoonji Kim,et al. Functional Studies of Five Toxin-Antitoxin Modules in Mycobacterium tuberculosis H37Rv , 2016, Front. Microbiol..
[49] A. Steyn,et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself , 2016, Nature Communications.
[50] K. Lewis,et al. High Persister Mutants in Mycobacterium tuberculosis , 2016, PloS one.
[51] Liem Nguyen. Antibiotic resistance mechanisms in M. tuberculosis: an update , 2016, Archives of Toxicology.
[52] Ofer Fridman,et al. Distinguishing between resistance, tolerance and persistence to antibiotic treatment , 2016, Nature Reviews Microbiology.
[53] Vikram Saini,et al. Ergothioneine Maintains Redox and Bioenergetic Homeostasis Essential for Drug Susceptibility and Virulence of Mycobacterium tuberculosis. , 2016, Cell reports.
[54] A. Chaudhury,et al. HIV-Associated TB Syndemic: A Growing Clinical Challenge Worldwide , 2015, Front. Public Health.
[55] G. Schoolnik,et al. Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. , 2015, The Journal of infectious diseases.
[56] D. Schnappinger,et al. Disruption of an M. tuberculosis Membrane Protein Causes a Magnesium-dependent Cell Division Defect and Failure to Persist in Mice , 2015, PLoS pathogens.
[57] Benjamin K. Johnson,et al. Slow growth of Mycobacterium tuberculosis at acidic pH is regulated by phoPR and host‐associated carbon sources , 2014, Molecular microbiology.
[58] E. Rubin,et al. How sisters grow apart: mycobacterial growth and division , 2014, Nature Reviews Microbiology.
[59] W. Jacobs,et al. Molecular Genetics of Mycobacteria, Second Edition , 2014 .
[60] Se Yeon Kim,et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.
[61] C. Nathan,et al. Whole Cell Screen for Inhibitors of pH Homeostasis in Mycobacterium tuberculosis , 2013, PloS one.
[62] C. Vilchèze,et al. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction , 2013, Nature Communications.
[63] K. Rhee,et al. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis , 2013, Proceedings of the National Academy of Sciences.
[64] A. Cataldi,et al. Virulence factors of the Mycobacterium tuberculosis complex , 2013, Virulence.
[65] Carl Nathan,et al. Fresh Approaches to Anti-Infective Therapies , 2012, Science Translational Medicine.
[66] J. Collins,et al. Heterogeneous Bacterial Persisters and Engineering Approaches to Eliminate Them This Review Comes from a Themed Issue on Genomics Edited More than One Way to Make a Persister Persisters and Physiological Heterogeneity Engineering Treatments for Persisters , 2022 .
[67] Ying Zhang,et al. Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis , 2011, Science.
[68] C. Sassetti,et al. Metabolic Regulation of Mycobacterial Growth and Antibiotic Sensitivity , 2011, PLoS biology.
[69] Eric Arnoult,et al. The challenge of new drug discovery for tuberculosis , 2011, Nature.
[70] A. Velayati,et al. Sequential adaptation in latent tuberculosis bacilli: observation by atomic force microscopy (AFM). , 2011, International journal of clinical and experimental medicine.
[71] N. Singhal,et al. Streptomycin induced protein expression analysis in Mycobacterium tuberculosis by two-dimensional gel electrophoresis & mass spectrometry. , 2010, The Indian journal of medical research.
[72] J. Flynn,et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.
[73] W. Bishai,et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. , 2009, The Journal of infectious diseases.
[74] Thomas Dick,et al. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis , 2008, Proceedings of the National Academy of Sciences.
[75] C. Senner,et al. Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.
[76] W. Hillen,et al. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice , 2007, Nature Medicine.
[77] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[78] H. Engelhardt,et al. The MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis. , 2004, Microbiology.
[79] James C. Sacchettini,et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.
[80] L. Wayne,et al. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.
[81] G. Hobby,et al. Observations on the Mechanism of Action of Penicillin.∗ , 1942 .